Baltic BioLabs Research Team 12 min read
Tirzepatide, the newest dual GLP-1/GIP receptor agonist, has a similar 5-day half-life, but limited data suggest potentially less gastric emptying delay compared to pure GLP-1 agonists due to dual receptor activation [30]
Since ME/CFS was psychologised at first, many patients were initially treated with antidepressants (60)
These are known as lipotropics, substances that help break down fat during metabolism in the body
Researchers have found diseases including cardiovascular disease, non-alcoholic fatty liver disease, diabetic chronic kidney disease, osteoarthritis, autoimmune disease, alcohol use disorder and more could be positively impacted by GLP-1RA therapy